Jeffrey M. Saland, Piero Ruggenenti, Giuseppe Remuzzi, and the Consensus Study Group Hemolytic uremic syndrome (HUS) is a rare disease of microangiopathic hemolytic anemia, thrombocytopenia, and renal impairment. Typical HUS follows a diarrheal illness caused by a verocytotoxin-producing bacterium, commonly Escherichia coli O157:H7, and resolves in most cases without sequelae. 1 Atypical HUS (aHUS) is much less common and has a considerably worse prognosis in terms of both mortality and development of ESRD. 2 Mutations in genes encoding complement regulatory proteins and secondary disorders of complement regulation seem to play a central role in the pathogenesis of most cases of aHUS. Triggering of an unregulated complement cascade is thought to damage endothelium, producing microangiopathic hemolytic anemia and thrombosis. Gene mutations are identified in at least 50% of cases. The most frequently reported mutations are in the gene encoding complement factor H (CFH) and account for 50 to 60% of cases associated with documented genetic abnormalities. Less frequent are mutations in the genes encoding membrane co-factor protein (MCP) and complement factor I (CFI) and are observed in approximately 20% and 10 to 15% of the overall disease-associated mutations, respectively. [3] [4] [5] [6] More recently, gain-of-function mutations in the genes encoding the complement-activating protein complement factor B (CFB) as well as complement C3 (C3) have been reported in a few cases with aHUS. 7, 8 Antibodies against factor H have also been observed in patients with aHUS, particularly children, and in most cases in association with homozygous deletion of the genes encoding complement factor H-related proteins 1 and 3 (CFHR1 and CFHR3). 9 Indeed, there is a growing list of the mutations, polymorphisms, and other complement abnormalities that alone or in combination may lead to aHUS. 8 -13 
KIDNEY TRANSPLANTATION AND RISK FOR DISEASE RECURRENCE
Compared with patients with typical HUS, those with aHUS also have worse outcomes after kidney transplantation, largely because of the high rates of disease recurrence. 14, 15 The disease recurs in nearly 80% of transplant recipients with CFH mutations, and recurrences are usually associated with graft loss. 2, 16, 17 Although the data are more limited because of a lower frequency of cases, similar rates of recurrence and graft loss after transplantation are reported in aHUS associated with a CFI mutation. Indeed, nine of 10 renal transplants in six patients with a CFI mutation were complicated by early recurrence and graft loss. The exceptional patient without early recurrence had a functioning graft for 11 yr. This patient then also lost the graft to recurrent disease and received a second transplant with no recurrence at 2 yr after transplantation. 3, 5, 6 Data regarding cases of Published online ahead of print. Publication date available at www.jasn.org.
aHUS related to CFB 8 or C3 mutations 7 are emerging and suggest these patients are also at risk for recurrence; however, outcome data are insufficient to be used as the basis for clinical recommendations. 13 Mutations in CFH, CFI, CFB, and C3 all lead to abnormalities in circulating complement components that are mainly produced by the liver. These abnormalities will persist after a kidney transplantation, and this may explain the very high rate of recurrences in these patients. In contrast, MCP is a transmembrane protein expressed by nearly all cell types, highly so in the kidney, where it functions locally to limit complement activity. This may explain why among individuals with aHUS secondary to MCP mutation, recurrence is unusual after transplantation of kidneys that, presumably, express normal MCP. 18 The risk for aHUS recurrence after isolated kidney transplantation is more difficult to quantify in those rare cases with combined mutations in two or even three different complement genes. We are aware of five such cases, in which outcomes after transplantation were, not surprising, varied. Two patients with combined heterozygous mutations, one involving MCP/CFH and the other involving MCP/CFI, had uneventful transplants without recurrences (International Registry of HUS and TTP, unpublished data). Seitz et al. 19 reported two other patients with combined MCP/ CFH mutations (patients 3 and 7) and one patient with three mutations involving MCP, CFH, and CFI (patient 8) who had aHUS recurrence; all received intensive plasma exchange, which allowed graft recovery in patients 3 and 8 but did not prevent graft loss in patient 7. One reported patient with CFH/CFI mutation had no recurrence through 5 yr after transplantation. 20 
EMERGENCE OF LIVER TRANSPLANTATION TO PREVENT RECURRENCE
Liver transplantation corrects the complement abnormality and prevents disease recurrence in patients with defects in genes encoding circulating complement proteins that are synthesized in the liver. With this rationale, a patient with recurrent aHUS and CFH deficiency received an auxiliary partial orthotopic liver to restore CHF bioavailability. Factor H plasma levels progressively increased and were persistently close to normal range from the eight posttransplantation day. During the subsequent 7 mo, the child developed posttransplantation lymphoproliferative disease, renal failure with pancytopenia, and red cell aplasia, a clinical scenario in which aHUS recurrence could not be excluded. Eventually, the patient succumbed to pneumonia and bacterial sepsis 11 mo after transplantation. 21, 22 In other patients with aHUS and ESRD, combined liver-kidney transplantation was explored as a way both to restore renal function and to prevent recurrence of aHUS related to a CFH mutation. The first report was about a child who had recurrent disease and was at imminent risk for death because he had no further vascular access for extracorporeal dialysis and the efficiency of peritoneal dialysis was rapidly declining. The child received an orthotopic split liver transplant followed by a kidney transplant from the same deceased donor. Kidney function promptly recovered, but, after an initial improvement, liver function progressively deteriorated and the child developed severe hepatic encephalopathy. A liver biopsy showed changes consistent with humoral hyperacute rejection. A second liver transplant was undertaken a few days later and was followed by prompt recovery of liver function, but the neurologic abnormalities only partially improved. On subsequent follow-up, the child had no sign of hemolysis or disease recurrence but died 3 yr later as a result of the neurologic sequelae. 23 Regardless of the unfortunate outcome, this was the first evidence that aHUS associated with a complement abnormality could be cured by combined liver-kidney transplantation. The clinical course of the second reported case was also complicated by irreversible liver failure with a fatal outcome just after transplantation. At autopsy, the liver showed widespread microvascular thrombosis with diffuse deposition of IgG, IgM, and complement membrane attack complex in liver sinusoids consistent with complement activation. 24 It was conjectured that the surgical stress with liver ischemia and reperfusion might have induced intense local complement activation that could not be regulated, as occurs normally, as a result of the deficiency in functional CFH. A reassessment of the histology material suggested that similar mechanisms might have been involved in the liver graft failure that complicated the course of the previously reported case. 23 Thus, combined liver-kidney transplantation seems to be an effective approach to prevent disease recurrence but is associated with an unexpected and unacceptable risk for premature and irreversible liver failure secondary to uncontrolled complement activation.
After these initial reports, a modified approach to combined liver-kidney transplantation that demonstrated no acute hepatic events and good long-term outcome was developed for a young child who had ESRD and whose other clinical options had been nearly exhausted. The pivotal modification was to exchange large quantities of plasma before transplantation with further plasma supplementation during the procedure. This both increased the bioavailability of functional factor H during the critical period needed for the liver graft to recover synthetic functions and, at the same time, removed the endogenous mutant CFH preventing possible antagonism of normal CFH supplied with plasma. 25 The modified, combined liverkidney transplant procedure also included empiric use of low molecular weight heparin and low-dosage aspirin to counteract the potential increased thrombogenicity associated with allograft endothelial activation and the additional clotting factors in the infused plasma. A second transplant in another child with a CFH mutation at the same center was also successful; in that case, a split liver graft was used. 26 The technique was successfully adopted, with few modifications, by a second center that also reported success with two children 27 and an adult patient (H. Jalanko, University Hospital for Children and Adolescents, Helsinki, Finland, December 15, 2007) all with CFH mutations.
After the success of the initial combined transplants undertaken with this modified protocol, a Consensus Conference on Kidney and Liver Transplantation in Atypical Hemolytic Uremic Syndrome was held in December 2007 to discuss this emerging procedure. The aim was to develop recommendations that would enable more widespread use of liver transplantation. Since the conference, a third center has used the technique to perform an isolated liver transplant in a child who had a CFH mutation and whose renal function had been maintained with long-term plasma therapy (D. Milford, The Children's Hospital, Birmingham, England, February 16, 2008) as well as a fourth center that undertook a combined liver-kidney transplant in a dialysis-dependent child with a CFH mutation (L. Milner, Floating Hospital for Children at Tufts University Medical Center, Boston, MA, May 9, 2008). These transplants have been uncomplicated to date. Most recently, a combined transplant for a child with imminent ESRD resulted in death. This was undertaken without additional modification at the center that developed the revised technique. Severe hemodynamic instability developed upon portal vein clamping. Additional plasma exchange treatments were provided, and although some postoperative improvement in liver function was noted, hepatic artery thrombosis occurred, followed by fatal hepatic encephalopathy. Histopathologic examination of hepatic graft excluded both thrombotic microangiopathy and hyperacute rejection; there was no deposition of C3 or Igs, although rare C1q and fibrinogen staining of central veins was present. Renal graft biopsy demonstrated acute tubular necrosis without aHUS. Although the experience since the conference has included this one fatal outcome, there remains consensus that this procedure, with proper consideration of individual risks and benefits, offers the best opportunity for long-term transplant success.
CONSENSUS RECOMMENDATIONS
What follows is the approach adopted by the consensus conference.
Recommendation 1: Initial Diagnosis and Management of aHUS
On the basis of a recent classification strategy 1 and in agreement with recommendations made by the European Pediatric Study Group for HUS, 28 Table 1 presents criteria to identify patients whose initial presentation with HUS is atypical. As shown in Table 1 , we recommend investigation and empiric treatment for all patients who present with certain atypical features, regardless of whether they have typical signs such as a prodromal diarrheal illness or evidence of sepsis/pneumonia caused by Streptococcus pneumoniae. We also recommend investigation and empiric treatment if none of those atypical features is present but typical features are absent. We are of the opinion that this pragmatic approach will not only identify patients who are most likely to have an underlying complement disorder but also increase the chance of a response to treatment.
Empiric Treatment.
For patients who satisfy these criteria, plasma exchange should be commenced as soon as a diagnosis of aHUS is established and continued as in the recommendations in Table 2 . We emphasize prompt empiric plasma exchange because clinical deterioration and irreversible renal or extrarenal manifestations may occur very rapidly.
Genetic Studies.
In conjunction with empiric management, accurate diagnosis of the disorder is critical and can be optimized by directed laboratory analyses, some that are widely available and some that are available only in specialized laboratories (Table 3). Genetic screening for CFH, CFI, MCP, CFB, and C3 mutations is indicated for the patient. Screening of available relatives may provide information about the pathogenicity of any mutations identified and highlight important coincident risk haplotypes in related genes; however, the benefits and risks of such screening should be carefully discussed before this is undertaken. Screening of all exons is recommended rather than "hot spot" analysis. Analysis of the copy number of the CFHR1 and CFHR3 genes should be considered, particularly when anti-CFH antibodies are detected. Accurate genetic diagnosis is essential if patients are to be considered for combined liver and kidney transplantation, liver transplantation, or isolated kidney transplantation. Finally, a rapid pace of discovery means the list of related genes is likely to expand in the future, and, as has occurred with previous 13, 29 screening recommendations, future updates will be required.
Referral to aHUS Registry. Enrollment of patients into national or international registries for the study of aHUS is encouraged for affected families. It is this voluntary participation and international collaboration that has produced the current knowledge base about this condition and thus enabled the development of these consensus recommendations. It is hoped that registry participation will lead to further improvement in the understanding and treatment of this rare illness. the vast majority of individuals with CFH or CFI mutations are at very high risk for recurrence and graft loss, 10 combined liver-kidney transplantation or liver transplantation should be considered for individuals with CFH or CFI mutations when the risk for recurrence associated with their specific mutation cannot be inferred on the basis of registry inquiry. Special consideration should be given to patients who have a CFH or CFI mutation and have aHUS but have preserved renal function through intermittent plasma therapy. We note that such patients have maintained a reasonable quality of life with individualized plasma therapy over an extended period of time. Although no other treatments are available, biologicals blocking complement activity, such as eculizumab, and purified factor H (yet to be developed) are major agents of interest. Although there is no knowing whether the future will find those agents either safe or effective, it is possible that intermittent plasma therapy over several years may provide time for such new treatments to reach the clinical arena. Unfortunately, the literature suggests at best variable response to plasma therapy, [35] [36] [37] and the combined clinical experience of the authors suggests that there is a high risk for progression to ESRD over several years for those using this treatment strategy; therefore, it is reasonable to consider isolated liver transplantation as an option for such patients to preserve native kidney function.
For patients who have had one or more episodes of aHUS but do not have ESRD, the degree of chronic kidney disease that is present should be established before the decision to recommend a liver transplantation alone versus combined liver-kidney transplantation is made. Although the literature does not paint a clear picture of the long-term risk to renal function after isolated liver transplantation, 38, 39 having experienced one or more episodes of aHUS must be considered a risk factor for chronic renal insufficiency after liver transplantation; therefore, in cases in which there is evidence of chronic kidney disease, we recommend that a renal biopsy be undertaken before isolated liver transplantation. Significant histologic abnormalities, in conjunction with the prospect of future nephrotoxicity as a result of posttransplantation use of calcineurin inhibitors, may reasonably indicate a high risk for short-term kidney failure and should be an indication for a combined transplant.
Because our understanding of aHUS is incomplete, we present in Table 5 situations in which it is not possible currently to make a recommendation for or against combined liver-kidney transplantation, liver transplantation, or isolated kidney transplantation. The number of patients who have combined mutations in two or three different complement genes and have had kidney transplantation is too few and the outcomes too varied to make a definitive recommendation for a first transplantation; however, combined transplantation is recommended for such patients if they have already experienced aHUS recurrence after isolated kidney transplantation. Patients with CHFR1-CFHR3 deletion with or without anti-CFH antibodies have unknown rates of success after isolated kidney transplantation.
Whether combined liver-kidney transplantation should be recommended for patients with C3 or CFB mutations is unclear. Although C3 is predominantly synthesized in the liver, 40 there is concern there may still be sufficient extrahepatic production of mutant protein for a patient to remain at risk for recurrent renal disease after a combined transplant. This is because the majority of individuals with aHUS-associated C3 mutations have gain-of-function mutations 7 and even residual mutant protein could prove pathogenic.
Whether the liver is the exclusive site of factor B production is also unclear, but the clinical phenotype of patients with aHUS related to a CFB mutation suggests the operative risk of a combined liverkidney transplant may be greater. Cerebrovascular disease, vasoactive phenom- Table 4 . Eligibility for combined liver and kidney transplant or liver transplant alone CFH or CFI mutation with the exceptions listed in Table 7 Less than 10% normal CFH levels in plasma Patients who have identified mutations of genes encoding and have aHUS recurrence after isolated kidney transplantation or have a family member who had the same mutation and had aHUS recurrence after isolated kidney transplantation HUS recurrence after isolated kidney transplantation in patients with identified mutations of genes that may have both hepatic and nonhepatic sites of expression and protein synthesis (see Table 7 ) Table 5 . Criteria for which currently available information is insufficient to indicate a specific recommendation for or against liver transplantation or combined liver and kidney transplantation versus isolated kidney transplantation . These features may require further investigation to determine the risk of combined transplantation. Moreover, plasma infusion and plasma exchange with fresh-frozen plasma (FFP) in patients with a gain-of-function CFB mutation induce increased complement activation, presumably because additional complement substrate is provided in the continued presence of active mutant CFB. At this stage, there is no solution to this issue; however, a potential approach is to provide plasmapheresis with albumin replacement to deplete the mutant CFB, followed by plasma exchange with FFP. Additional plasma exchanges with FFP would be required to maintain the effect. The effectiveness and duration of this approach are unknown and will likely vary from patient to patient.
Recommendation 3: Surgical and Perioperative Management
In contrast to the poor results of isolated kidney transplantation, the outcome of isolated liver or combined liver-kidney transplantation performed using the guidelines in Table 6 have been successful in seven of eight cases. These preliminary outcome results are consistent with the 3-mo (85% pediatric, 92% adult) and 1-yr (85% children, 85% adult) patient survival rates after combined liver-kidney transplantation for other indications. 41 Thus, despite the limited experience, it is possible to recommend, with appropriate consideration of individual risk and benefit, that this approach be used for all patients receiving a combined liver-kidney transplant or a liver transplant alone according to the criteria listed in Table 4 .
Intensified Plasma Therapy.
We emphasize strongly the importance of preoperative plasma exchange and intraoperative plasma infusion. These together allow the depletion of mutant complement regulators and replenish wild-type regulators, thereby facilitating control of the complement activation associated with the surgical procedure. 42, 43 It is likely that individual variability in the amount of plasma required to control complement activation and clinical circumstances may dictate that more be used than recommended in this statement. The amount of required plasma may also depend on how long it takes for the transplanted liver to establish its synthetic function and the rate of synthesis of complement regulatory proteins. Patients with surgical complications leading to prolonged warm ischemia and delayed liver graft function will probably require more plasma over an extended period.
Anticoagulation.
Anticoagulation was used in each of the successful procedures to date. Because of this and because it was recently established that the coagulation pathways SPECIAL ARTICLE www.jasn.org themselves activate complement, we recommend continued use of anticoagulation using a standard prophylactic regimen as detailed in Table 6 . [25] [26] [27] 44 Surgical Procedure. Although both split and whole liver grafts have been used with success, we recommend a minimum graft mass of 2% of the recipient's mass. We do not recommend auxiliary grafts for the following reasons. First, hepatic graft rejection might not be clinically apparent yet abruptly result in recurrent aHUS. Second, without removing the source of mutant proteins from the native liver, one cannot be certain that the continued presence of mutant complement proteins will not interfere with the function of wild-type protein. 45, 46 Immunosuppression. The consensus statement makes no specific recommendations about immunosuppression protocols. In particular, aHUS is not considered per se a specific contraindication to treatment with calcineurin inhibitors; however, initial immunosuppression with mammalian target of rapamycin inhibitors is not encouraged in the absence of clear clinical advantages because of the possible association with impaired wound healing and delayed graft function. 47 
Recommendation 4: Use of Isolated Kidney Transplantation
At present, there is no scientific rationale for liver transplantation for patients with no mutations identified in any of the aforementioned complement genes (Table 7). A small minority of patients with CFH or CFI mutations may reasonably be offered isolated kidney transplantation. These exceptional patients include those who have affected family members (with the same mutation) who have had a successful isolated kidney transplant or patients who carry an isolated mutation known from data recorded in the international registries to be at "lower risk" for posttransplantation recurrence. A preliminary report from the French cohort described a successful kidney transplant without recurrent aHUS in a young child with anti-CFH autoantibodies, 48 and there seems to be little reason to suggest that liver transplantation per se would benefit such patients. Rather, an antibody-depleting strategy such as the one reported is recommended.
Plasma Therapy.
On the basis of expert opinion, prophylactic plasma therapy is recommended preoperatively, postoperatively, and under certain clinical conditions outlined in Table 8 for patients for whom isolated kidney transplantation is undertaken. This recommendation reflects the report of a child who had ESRD secondary to familial aHUS and a CFH mutation and underwent successful kidney transplantation followed by long-term prophylactic plasma exchange. 35 Two recurrences of aHUS occurred in association with cytomegalovirus infections, but remission was achieved in each instance with increased frequency of plasma exchange. 33 If aHUS does recur after isolated kidney transplantation, then we recommend that liver or liver-kidney transplantation be performed. In addition, genetic analysis should be repeated for patients who have an unsuccessful isolated kidney transplantation as a result of aHUS recurrence. Patients and clinicians are encouraged to update national and international registries after transplantation to guide management of future cases.
Living-Related Donors.
We strongly recommend that organ donation from related individuals be avoided even if the presence of known mutations in the donor is excluded. This is because the full host of complement-related genes and mutations associated with disease has not been elucidated. As suggested by genetic analysis of families, most aHUS-associated mutations have an incomplete penetrance, and healthy related carriers are frequently Table 5 ) for patients who have certain gene mutations and (1) have aHUS recurrence after isolated kidney transplantation or (2) have a family member who had the same mutation and had aHUS recurrence after isolated kidney transplantation. Table 8 . Guidelines to perioperative treatment and follow-up of patients receiving an isolated kidney transplant Dialysis better before plasma exchange in all cases mandatory before plasma exchange in cases with signs of complement activation (e.g., angioedema) during dialysis Plasma exchange a minimum of 1.5 Vol of FFP is exchanged within 4 to 6 h of surgery exchange must be repeated if surgery is delayed and within 24 h after transplantation therapy is continued following the same schedule as for patients initially presenting with aHUS (see Table 1 ). in the setting of postoperative complications (e.g., surgical revision, delayed graft function, rejection) or for definitive recurrence of HUS, plasma exchange is instituted and following the same schedule as for patients initially presenting with aHUS (see Table 2 ) anti-factor H antibodies, if present, must be depleted to very low levels; additional immunosuppression may be indicated (see text and reference 48 ) Monitoring close monitoring for early detection of recurrent HUS, particularly in the setting of acute illness or surgery, is recommended identified. 3 There is a remote likelihood that such mutations may be present even in unrelated donors; therefore, for patients who have the characteristics listed in Table  7 and undergo isolated kidney transplantation, when possible, we recommend genetic screening of donors through the registry to exclude healthy carriers of known mutations and for the purpose of future categorization of additional risk haplotypes among complement-related genes.
CONCLUSIONS
The recommendations of our consensus conference are the result of combined clinical experience, shared research expertise, and a review of the literature and registry information. The statement defines groups for whom isolated kidney transplantation is extremely unlikely to be successful as a result of disease recurrence and for whom a combined liver transplant is recommended and also defines those for whom kidney transplantation remains a viable option. The gravity of risk associated with liver or combined transplantation as a clinical procedure has not been eliminated completely, and that assessment of risk and benefit requires careful and individual attention. Nonetheless, in contrast to early experience, the success of the protocol and approach outlined in this statement shows that combined liver-kidney transplantation or isolated liver transplantation is the preferred therapeutic option in many cases. whose participation in various national and international registries has made possible the advances in understanding and treatment outlined in this statement. We are extremely grateful to Timothy Goodship, who extensively and critically revised the whole manuscript, and to Marina Noris, who contributed substantially to revise the genetic sections. We also thank Sara Gamba for the precious contribution of organizing the consensus meeting and Manuela Passera for help in preparing the manuscript. This work has been partially supported by a grant from Fondazione ART Per La Ricerca Sui Trapianti (Milan, Italy).
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